David Lane Group
The protein p53, widely known as the guardian of the genome, was discovered by Prof. Sir David Lane in 1979 and has over the years been recognized as a tumor suppressor gene mutated in more than half of all malignant tumors occurring in adults. Apart from its role as a tumor suppressor, p53 has been shown to be involved in numerous regulatory cell functions. Research in our lab is focused on understanding the many facets of p53 biology in malignant and normal cells. We employ cutting edge technology such as mass spectometry, advanced microscopy, multi-color flow cytometry and imaging cytometry to this end and strive to translate our findings to the clinic.
Projects withing the David Lane Group
|Cecilia Bosdotter||Laboratory technician|
|Nicolas Fritz||Senior research specialist|
|Katrine Ingelshed||PhD student, Graduate Student|
|Michael Landreh||Assistant professor|
|Danai Lianoudaki||Laboratory technician|
|Tanzina Mollick||PhD student, Graduate Student|
The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
Cancer Res. 2018 Sep;78(17):5084-5093
Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone.
J Phys Chem Lett 2018 Jul;9(14):4082-4086
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine.
Cell Rep 2018 Jan;22(1):299-312
Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity.
Cancer Res. 2017 08;77(16):4342-4354
Exploiting the p53 Pathway for Therapy.
Cold Spring Harb Perspect Med 2017 Mar;7(3):
Cancer. p53, guardian of the genome.
Nature 1992 Jul;358(6381):15-6
T antigen is bound to a host protein in SV40-transformed cells.
Nature 1979 Mar;278(5701):261-3
Tometebodavägen 23A (Gamma building, 5th floor),
The p53 lab in singapore is focusing on the development of new therapies, new diagnostics and new discoveries in the p53 pathway.
More information on the website